What is Emboline?
Founded in 2011 by Amir Belson, Emboline specializes in the development of the Emboliner Embolic Protection Catheter. The company operates at the intersection of interventional cardiology and neuroprotection, addressing a critical unmet need in the medical device sector. Unlike traditional embolic protection systems, the Emboliner is engineered to provide comprehensive cerebral protection while simultaneously capturing non-cerebral debris. This dual-action capability positions Emboline as a disruptive force in the medical technology landscape, particularly as the demand for safer, more reliable outcomes in transcatheter aortic valve replacement (TAVR) procedures continues to rise globally.
How much funding has Emboline raised?
Emboline has raised a total of $80M across 4 funding rounds:
Series B
$10M
Other Financing Round
$5M
Series C
$10M
Series D
$55M
Series B (2018): $10M with participation from ShangBay Capital and SV Tech Ventures
Other Financing Round (2020): $5M led by Undisclosed
Series C (2021): $10M, investors not publicly disclosed
Series D (2021): $55M featuring ShangBay Capital, SV Tech, Matrix Capital Management, and Global Assets Investment
Key Investors in Emboline
ShangBay Capital
ShangBay Capital is a venture capital firm that specializes in medical devices, biotechnology, and healthcare, focusing on both seed and early-stage investment opportunities.
Matrix Capital Management
Matrix Capital Management is an investment fund based in Waltham, Massachusetts, with a dedicated focus on the technology and life sciences sectors.
SV Tech Ventures
SV Tech Ventures provides strategic backing to emerging technology companies, leveraging deep industry expertise to support long-term growth and innovation.
What's next for Emboline?
With the recent influx of capital, Emboline is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its clinical trial footprint. The company's strategic roadmap likely involves navigating the regulatory pathways required for broader market adoption of the Emboliner device. As the firm transitions from an emerging medical device developer to a commercial-stage entity, the focus will shift toward establishing clinical efficacy benchmarks and securing widespread adoption among interventional cardiologists. This growth trajectory is supported by a robust intellectual property portfolio and a clear mandate to reduce procedural complications in the rapidly evolving field of structural heart disease.
See full Emboline company page
